Plus Therapeutics Inc
PSTV
Company Profile
Business description
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
Contact
2710 Reed Road
Suite 160
HoustonTX77051
USAT: +1 737 255-7194
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
21
Stocks News & Analysis
stocks
Picking dividend shares in 2026? Here’s where to look
A new report from Morningstar shows opportunities for income investors.
stocks
Ahead of earnings, is Nvidia a buy, a sell, or fairly valued?
With outstanding long-term estimates, here’s what we think of Nvidia stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,826.40 | 80.80 | 0.92% |
| CAC 40 | 7,953.77 | 14.16 | -0.18% |
| DAX 40 | 23,162.92 | 17.61 | -0.08% |
| Dow JONES (US) | 46,138.77 | 47.03 | 0.10% |
| FTSE 100 | 9,507.41 | 44.89 | -0.47% |
| HKSE | 25,867.87 | 37.22 | 0.14% |
| NASDAQ | 22,564.23 | 131.38 | 0.59% |
| Nikkei 225 | 49,774.97 | 1,237.27 | 2.55% |
| NZX 50 Index | 13,439.40 | 112.50 | 0.84% |
| S&P 500 | 6,642.16 | 24.84 | 0.38% |
| S&P/ASX 200 | 8,545.70 | 77.70 | 0.92% |
| SSE Composite Index | 3,961.71 | 14.96 | 0.38% |